Naratriptan drug interactions: Difference between revisions
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Naratriptan}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailym...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Drug Interactions== | |||
======Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome====== | |||
Cases of life-threatening serotonin syndrome have been reported during combined use of SSRIs or SNRIs and triptans (see WARNINGS). | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39c658d3-5bc8-4f81-9837-1c4edcf1b6c2 | publisher = | date = | accessdate = }}</ref> | ======Ergot-Containing Drugs====== | ||
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated (see CONTRAINDICATIONS). | |||
======Other 5-HT1 Agonists====== | |||
The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients. Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended (see CONTRAINDICATIONS). | |||
======Drug/Laboratory Test Interactions====== | |||
Naratriptan tablets are not known to interfere with commonly employed clinical laboratory tests.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NARATRIPTAN TABLET, COATED [SANDOZ INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=39c658d3-5bc8-4f81-9837-1c4edcf1b6c2 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 20:09, 3 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Drug Interactions
Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome
Cases of life-threatening serotonin syndrome have been reported during combined use of SSRIs or SNRIs and triptans (see WARNINGS).
Ergot-Containing Drugs
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated (see CONTRAINDICATIONS).
Other 5-HT1 Agonists
The administration of naratriptan with other 5-HT1 agonists has not been evaluated in migraine patients. Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended (see CONTRAINDICATIONS).
Drug/Laboratory Test Interactions
Naratriptan tablets are not known to interfere with commonly employed clinical laboratory tests.[1]
References
Adapted from the FDA Package Insert.